Oxymetazoline 1% cream in erythema of rosacea: a profile of its use in the USA
- 10 Downloads
Oxymetazoline 1% cream (Rhofade™) is a topical α1A-agonist approved to treat persistent facial erythema associated with rosacea in adults in the USA. It relieves the redness of affected skin by inducing vasoconstriction in the superficial skin vasculature. In clinical trials, application of oxymetazoline cream for up to 1 year was effective and generally well tolerated in rosacea patients with persistent erythema, with a low incidence of application-site reactions and rebound erythema.
This manuscript was reviewed by: R.M. Hoover, Department of Pharmacy Practice and Administrative Sciences, Idaho State University, Pocatello, ID, USA; L.H. Kircik, Icahn School of Medicine at Mount Sinai, New York, NY, USA; F. Vilchez-Márquez, Department of Dermatology, Hospital de Guadix, Guadix, Spain. During the peer review process, the marketing-authorization holder of oxymetazoline 1% cream was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
K. McKeage and K.A. Lyseng-Williamson are employees of Adis/Springer, are responsible for the article content and declare no conflicts of interest.
- 7.Rhofade™ (oxymetazoline hydrochloride) cream, for topical use: US prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ba1cc5b-4f7f-491b-a5af-a6a14fb5affd. Accessed 12 Nov 2018.
- 13.Mirvaso® (brimonidine) topical gel, 0.33%: US prescribing information. Fort Worth (TX): Galderma Laboratories; 2017.Google Scholar
- 14.Tian M, Hsia E, Andrews-Jones L, et al. The alpha adrenergic receptor agonist oxymetazoline decreases erythema and inflammation in a UVB-induced sunburn model [abstract no. 1251]. J Invest Dermatol. 2013;133(Suppl 1):S213.Google Scholar
- 15.Hsia E, Tian M, Santori E, et al. The alpha adrenergic receptor agonist oxymetazoline inhibits temperature-induced vasodilation and LL-37-induced skin inflammation [abstract no. 021]. J Invest Dermatol. 2012;132(Suppl. 1):S4.Google Scholar
- 19.Stein-Gold L, Kircik LH, Draelos ZD, et al. Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: pooled analysis of the two phase 3, 29-day, randomized, controlled REVEAL trials. J Am Acad Dermatol. 17(11):1201–8.Google Scholar
- 22.Gold MH, Lebwohl M, Biesman BS, et al. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistant erythema of rosecea through 52 weeks of treatment [letter]. J Am Acad Dermatol. 79(3):e57–e59.Google Scholar